康柏西普联合丝裂霉素 C 增强型小梁切除术治疗新生血管性青光眼的疗效及安全性。

The efficacy and safety of intravitreal conbercept combined with mitomycin C augmented trabeculectomy for treating neovascular glaucoma.

机构信息

Department of Ophthalmology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China.

Department of Urology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China.

出版信息

Discov Med. 2020 Mar-Apr;29(157):113-118.

PMID:33002407

Abstract

AIM

To investigate the efficacy and safety of intravitreal Conbercept (IVC) and trabeculectomy for treating neovascular glaucoma (NVG).

METHODS

We retrospectively reviewed a total of 29 eyes from 29 NVG patients. All patients received preoperative IVC combined with mitomycin C (MMC) augmented trabeculectomy with a 12-month follow-up. The best-corrected visual acuities (BCVA), intraocular pressure (IOP), and cumulative survival rate were calculated.

RESULTS

All 29 cases had complete regression of iris neovascularization at 7 days after the combination treatment, and 2 cases had residual iris neovascularization which regressed completely 1 month later. IOP decreased while BCVA improved significantly following the combination treatment. The success rates were 96.6%, 93.1%, 89.7%, 86.2%, and 82.8% at 1 week, 1, 3, 6, and 12 months after trabeculectomy, respectively. IVC injection combined trabeculectomy had few complications.

CONCLUSIONS

IVC injection of conbercept combined with trabeculectomy is effective and safe for the treatment of NVG.

摘要

目的

探讨玻璃体内注射康柏西普（IVC）联合小梁切除术治疗新生血管性青光眼（NVG）的疗效和安全性。

方法

回顾性分析 29 例（29 眼）NVG 患者，均行术前 IVC 联合丝裂霉素 C（MMC）增强小梁切除术，随访 12 个月。计算最佳矫正视力（BCVA）、眼压（IOP）和累积生存率。

结果

联合治疗后 7 天所有病例虹膜新生血管均完全消退，2 例残留虹膜新生血管，1 个月后完全消退。联合治疗后眼压降低，BCVA 明显提高。小梁切除术后 1 周、1、3、6、12 个月的成功率分别为 96.6%、93.1%、89.7%、86.2%和 82.8%。IVC 注射康柏西普联合小梁切除术并发症少。